Patent ID: 7740841

Claim:
A method of treating a solid tumor in a human patient by inhibiting angiogenesis, comprising: administering to the human patient comprising a solid tumor selected from the group consisting of breast carcinoma, lung carcinoma, prostate carcinoma, colon carcinoma, ovarian carcinoma, neuroblastoma, central nervous system tumor, glioblastoma multiforme and melanoma: (a) an antibody or binding fragment thereof that (i) specifically binds to a flk-1/KDR receptor and (ii) inhibits angiogenesis; and (b) a chemotherapeutic agent having anti-angiogenic activity selected from the group consisting of vincristine, vinblastine, vinorelbine, vindesine, paclitaxel, docetaxel, 5 FU, cisplatin, carboplatin, irinotecan, topotecan and cyclophosphamide, in amounts and frequencies effective, in combination, to inhibit formation of blood vessels supplying the solid tumor while minimizing or preventing toxicity of the chemotherapeutic agent, wherein the chemotherapeutic agent is administered at a dose intensity of less than about 10% of the dose intensity of the chemotherapeutic agent when used in a conventional chemotherapeutic regimen, wherein said administering is continued over a period of time from about 10 days to about 6 months, and wherein synergistic tumor inhibition is obtained.